The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AKARI THERAPEUTICS PLC SPONSORED ADR 00972G108 2,029 139,899 SH   DFND 1 139,899 0 0
ALDEYRA THERAPEUTICS INC COMMON 01438T106 428 63,146 SH   DFND 1 63,146 0 0
AQUINOX PHARMACEUTICALS INC COMMON 03842B101 10,101 809,415 SH   DFND 1 809,415 0 0
ARADIGM CORP COM NO PAR NEW 038505400 4,373 1,101,513 SH   DFND 1 1,101,513 0 0
BLUEPRINT MEDICINES CORP COMMON 09627Y109 8,261 313,626 SH   DFND 1 313,626 0 0
CELLADON CORP COMMON 15117E107 2,058 1,399,991 SH   DFND 1 1,399,991 0 0
ESSA PHARMA INC COMMON 29668H104 119 28,100 SH   DFND 1 28,100 0 0
KURA ONCOLOGY INC COMMON 50127T109 5,499 654,595 SH   DFND 1 654,595 0 0
MIRATI THERAPEUTICS INC COMMON 60468T105 63,934 2,023,232 SH   DFND 1 2,023,232 0 0
NABRIVA THERAPEUTICS AG SPONSORED ADR 62957M104 1,688 176,710 SH   DFND 1 176,710 0 0
NEXVET BIOPHARMA PUB LTD CO ORD SHS G6503X109 528 154,840 SH   DFND 1 154,840 0 0
SEATTLE GENETICS INC COMMON 812578102 7,181 160,000 SH   DFND 1 160,000 0 0
SOPHIRIS BIO INC COM NEW 83578Q209 1,780 1,000,000 SH   DFND 1 1,000,000 0 0
VITAE PHARMACEUTICALS INC COMMON 92847N103 4,530 250,270 SH   DFND 1 250,270 0 0
ZOGENIX INC COM NEW 98978L204 3,317 225,000 SH   DFND 1 225,000 0 0